1·Patients get rituximab through infusion into a vein (IV) at the oncologist's office or clinic.
患者可在肿瘤专家的办公室或门诊接受静脉注入美罗华。
2·Rituximab specifically recognizes and attaches to a protein called CD20 that is found on the surface of some lymphocytes.
美罗华特异的识别和附着于在一些淋巴细胞表面可以找到蛋白cd 20。
3·Rituximab may be effective in controlling MCD in a subset of patients.
美罗华可有效地控制麦当劳中的一个子集的患者。
4·We observed an aggravation of concomitant cutaneous Kaposi sarcoma, and hypothesize that rituximab could have exacerbated it.
我们观察到的恶化伴随皮肤卡波西氏肉瘤，并推测这种美罗华可能加剧。
5·Addition of GM-CSF did not impair tolerance to rituximab, and adverse events were rare and mild.
添加GM-CSF不减弱美罗华的耐受性，不良反应很少，并且很轻。